Stay updated on Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.

Latest updates to the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed two significant studies related to the efficacy and safety of Nivolumab in treating metastatic esophagogastric cancer and recurrent metastatic urothelial carcinoma, which may impact the information available to readers about these treatments.SummaryDifference0.7%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version of the clinical trial study, with the previous version's details about tumor types and enrollment status removed. The new version includes a focus on advanced or metastatic solid tumors and updates the revision number.SummaryDifference11%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 27, 2024.SummaryDifference0.6%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.